紫杉醇联合卡铂化疗并同步放疗在中晚期宫颈癌治疗中的临床疗效分析(1)
 |
| 第1页 |
参见附件。
【摘要】 目的：探讨紫杉醇联合卡铂化疗并同步放疗治疗中晚期宫颈癌近期及远期疗效。方法：选择近期于本科就诊的135例晚期宫颈癌患者，根据治疗方案，分为放疗结合紫杉醇及卡铂联合化疗治疗的观察组及仅采用单纯放疗治疗的对照组，观察两组的近期及远期临床效果，并分析两组并发症的发生率。结果：紫杉醇联合卡铂同步放疗观察组治疗后，完全缓解率、总体有效率分别为17.3%、60.0%，显著高于对照组的6.0%、38.0%；随访发现，观察组3年生存率、5年生存率分别为77.3%、60.0%；局部复发率、远处转移率分别为14.7%，9.3%，平均生存时间为(3.5±2.6)年，均显著优于对照组(P<0.05)。观察组毒副反应发生率显著高于对照组。结论：紫杉醇联合卡铂同步放疗治疗中晚期宫颈癌，可显著增强治疗效果，延长患者生存时间。
【关键词】 紫杉醇； 卡铂； 放疗； 中晚期宫颈癌
Analysis of Clinical Efficacy of Paclitaxel and Carboplatin Chemotherapy in Combination with Radiotherapy in the Treatment of Advanced Cervical Cancer / GAO Gui—chen.// Medical Innovation of China，2012，9(29)：008—010
【Abstract】 Objective：To investigate the clinical efficacy of paclitaxel and carboplatin chemotherapy in combination with radiotherapy in the treatment of advanced cervical cancer. Method：125 cases of advanced cervical cancer patients in our department recently， according to the treatment program，they were divided into radiotherapy combined with paclitaxel and carboplatin combination chemotherapy in the observation group and for control group， only treatment with radiotherapy alone. The two groups were observed near future and far clinical effects and analysis of the two groups the incidence of complications. Result：Paclitaxel and carboplatin concurrent with radiotherapy treatment in the observation group， complete remission rate， overall efficiency were 17.3%， 60.0%， which were significantly higher than 6.0%， 38.0%； follow—up found that 3—year survival rate of the observation group， 5—year survival rates were 77.3%， 60.0% respectively； local recurrence rate， distant metastasis rates were 14.7%， 9.3%， meaned survival time (3.5±2.6) years， which were significantly better than the control group (P<0 ......
您现在查看是摘要介绍页，详见PDF附件(2954kb)。